Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
This study comprises 3 years' PMS for emicizumab. No TEs/TMA associated with BPAs occurred. Results further support the safety and effectiveness of emicizumab in Japanese patients with congenital HA with inhibitors.
Authors
- Midori Shima (ORCID: https://orcid.org/0000-0002-5922-7061)
- Lyu Ji
- Tadashi Matsushita (ORCID: https://orcid.org/0000-0002-3646-3125)
- Masanori Matsumoto (ORCID: https://orcid.org/0000-0002-7243-3126)
- Chihiro Sugita (ORCID: https://orcid.org/0000-0001-9514-6798)
- Katsuyuki Fukutake (ORCID: https://orcid.org/0000-0003-0438-8957)
- Mika Kawano
- Yoshihiko Sugimura
Institutions
- Nagoya University Hospital (JP)
- Ogikubo Hospital (JP)
- Chugai Pharma (United States) (US)
- Nara Medical University (JP)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1111/hae.70162
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nara Medical University
- Chugai Pharmaceutical